Current progress in the treatment of chronic hepatitis C

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

419

HTML

5452

Figures (1-2)

228

Tables (1-2)

235

Sum=6334

Nov 14, 2012 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Nov 14, 2012; 18(42): 6060-6069
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060

Table 1 New agents against hepatitis C virus currently evaluated in phase II or III trials

Drug	Company
NS3/4A protease inhibitors
First generation, linear
Boceprevir (Approved)	MERCK
Telaprevir (Approved)	JANSSEN
Narlaprevir	MERCK
First generation, macrocyclic
BI201335	BOEHRINGER Ingelheim
TMC435	TIBOTEC/JANSSEN
Danoprevir	ROCHE
Vaniprevir	MERCK
Asunaprevir	BRISTOL-MYERS SQUIBB
ABT-450	ABBOTT
GS-9451	GILEAD
GS-9256	GILEAD
ACH-1625	ACHILLION
Second generation, macrocyclic
MK-5172	MERCK
Nucleos(t)ide analogue inhibitors of HCV polymerase
PSI/GS-7977	PHARMASSET/GILEAD
Mericitabine	ROCHE
IDX-184	IDENIX
Non-nucleoside analogue inhibitors of HCV polymerase
Tegobuvir	GILEAD
Filibuvir	PFIZER
ANA-598/Setrobuvir	ANADYS/ROCHE
BI207127	BOEHRINGER Ingelheim
ABT-333	ABBOTT
ABT-072	ABBOTT
VX-222	VERTEX
NS5A inhibitors
Daclatasvir	BRISTOL-MYERS SQUIBB
GS-5885	GILEAD
GSK2336805	GSK
Cyclophilin inhibitors
Alisporivir¹	NOVARTIS
SCY-635	Scynexis

¹On hold by the United States Food and Drug Administration because of toxicity (pancreatitis cases with one death). HCV: Hepatitis C virus.

Citation: Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18(42): 6060-6069
URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6060.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6060